2923008-66-4

GSK_WRN4 is a WRN helicase inhibitor (pIC50=7.6) with anticancer activity. GSK_WRN4 selectively inhibits the growth of MSI tumor cells in vitro and in vivo by inducing DNA double-strand breaks, particularly at expanded TA repeats and DNA damage regions[1].

[1] Picco, et al. "Novel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells." Cancer Discovery 14.8 (2024): 1457-1475. DOI:10.1158/2159-8290.CD-24-0052